Lipid Nanorod-Mediated Codelivery of Inflammasome and STAT3 Inhibitors Attenuates DSS-Induced Colitis
ACS Nano Medicine · 09.11.2026
DOI: 10.1021/acsnanomed.6c00261 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 09.11.2026. Verfasst von Maharshi Debnath und 5 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben. Gefördert von: National Institute of General Medical Sciences, National Science Foundation.
Abstract (Originalsprache)
Ulcerative colitis (UC) is a complex inflammatory bowel disease driven by the coordinated activation of multiple immune pathways, making single-target therapies often insufficient for disease control. Here, we engineered a dual drug-loaded lipid nanorod platform designed to leverage the enhanced cellular internalization of rod-shaped nanoparticles to simultaneously inhibit complementary inflammatory pathways in dextran sulfate sodium (DSS)-induced colitis, including NLRP3 and AIM2 inflammasome signaling and IL-6/STAT3-mediated inflammation, thereby representing a multimechanistic nanotherapeutic strategy. Therapeutic efficacy was evaluated in an acute DSS-induced colitis mouse model and compared with the corresponding free drug combination and the clinical comparator, 5-aminosalicylic acid (5-ASA). Treatment with the dual drug-loaded nanorods significantly mitigated body weight loss (3-fold lower reduction), preserved colon length, and reduced systemic IL-1β (10-fold) relative to the control groups, while demonstrating superior therapeutic efficacy compared with the corresponding free drug combination. Mechanistic studies revealed simultaneous suppression of NLRP3 and AIM2 inflammasome expression, reduced IL-1β production, and marked inhibition of caspase-1 activation, Gasdermin D cleavage, and STAT3 phosphorylation, indicating coordinated regulation of both inflammasome-driven pyroptosis and IL-6-mediated STAT3 signaling cascades. Collectively, this study establishes dual drug-loaded lipid nanorods as a multipathway immunomodulatory platform for treating experimental colitis and supports coordinated nanotherapy as a promising strategy for inflammatory bowel disease.
Förderung
- National Institute of General Medical Sciences
- National Science Foundation
Zitieren
APA
Debnath, M., Malhotra, M., Fish, A., Forster, J., Basarboliev, O., & Kulkarni, A. (2026). Lipid Nanorod-Mediated Codelivery of Inflammasome and STAT3 Inhibitors Attenuates DSS-Induced Colitis. ACS Nano Medicine. https://doi.org/10.1021/acsnanomed.6c00261
Vancouver
Debnath M, Malhotra M, Fish A, Forster J, Basarboliev O, Kulkarni A. Lipid Nanorod-Mediated Codelivery of Inflammasome and STAT3 Inhibitors Attenuates DSS-Induced Colitis. ACS Nano Medicine. 2026. doi:10.1021/acsnanomed.6c00261
BibTeX
@article{Debnath2026,
author = {Debnath, Maharshi and Malhotra, Mehak and Fish, Adam and Forster, James and Basarboliev, Orlin and Kulkarni, Ashish},
title = {Lipid Nanorod-Mediated Codelivery of Inflammasome and STAT3 Inhibitors Attenuates DSS-Induced Colitis},
journal = {ACS Nano Medicine},
year = {2026},
doi = {10.1021/acsnanomed.6c00261}
}
EUVIMED